Development of COPD hand-held device

Glyconics is an innovative diagnostics company which is using a novel approach to the diagnosis and monitoring of respiratory disease.  It uses Infrared Spectroscopy to analyse sputum samples for specific biomarkers characteristic of chronic obstructive pulmonary disease (COPD) and the technology has utility in clinical management and the development of COPD therapeutics.

‌The company has been working in collaboration with Swansea University to develop a hand-held miniaturised device to diagnose and predict the exacerbation of Chronic Obstructive Pulmonary Disease in patients.

Researchers at Swansea University’s Centre for NanoHealth have developed a diagnostic device utilising infrared COPD biomarkers and modern electronic and optical components; the ultimate goal is to optimize the hand-held, miniaturised FTIR device for easy detection at point-of-care and disease monitoring by healthcare workers at the point-of-care.

After completing a Phase 1 study funded through InnovateUK they are preparing the ground for a full Phase 2 project, through evaluation of the technical, clinical, regulatory, and commercial viability of the technology, and the preparation of a full implementation and commercial strategy.  With the support of the Centre for NanoHealth, Glyconics have been awarded an InnovateUK Small Business Research Initiative for Healthcare (SBRI Healthcare) development contract for an initial feasibility study to assess the clinical performance of the miniaturised FTIR device.

The development contract from SBRI Healthcare will enable the implementation of a feasibility study to explore the potential to provide a technology-based solution that can be simply introduced as a means to identify disease severity, disease progression and an early indication of exacerbation.

Dr Paul Lewis, Chief Scientific Officer for Glyconics Ltd said ‘The Centre for NanoHealth has played a major role both in the biomarker discovery process to identify changes in COPD patients and the development of the infrared spectroscopy device we are now looking to commercialize. The state-of-the-art equipment and expertise at CNH has helped us rapidly complete R&D and enhanced our ability to secure further investments more quickly.